Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
AstraZeneca
Harvard Business School
Dow
Express Scripts

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,879,067

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,879,067
Title:Stabilized liquid anti-RSV antibody formulations
Abstract: The present invention provides liquid formulations of SYNAGIS.RTM. or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulation exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS.RTM. or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS.RTM. or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulation are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
Inventor(s): Oliver; Cynthia N. (North Potomac, MD), Shane; Erica (McLean, VA), Isaacs; Benjamin S. (Andover, MA), Allan; Christian B. (Brookeville, MD), Chang; Stephen T. (Frederick, MD)
Assignee: MedImmune, LLC (Gaithersburg, MD)
Application Number:15/041,295
Patent Claims:1. A method of purifying and formulating a liquid palivizumab formulation comprising at least 15 mg/ml of palivizumab, or an antigen-binding fragment thereof, and histidine in an aqueous carrier, wherein the histidine concentration is about 1 mM to about 100 mM and wherein said formulation is substantially free of surfactant, inorganic salts or other excipients; wherein the method comprises maintaining the palivizumab, or an antigen-binding fragment thereof, in an aqueous solution at all times during preparation.

2. A method of preparing a liquid formulation of palivizumab, or an antigen-binding fragment thereof, the method comprising: diafiltering a preparation of palivizumab, or an antigen-binding fragment thereof, into a formulation buffer to obtain a liquid formulation of palivizumab, or an antigen-binding fragment thereof; wherein the preparation of palivizumab, or an antigen-binding fragment thereof, comprises about 15 mg/ml to about 300 mg/ml palivizumab, or an antigen-binding fragment thereof; wherein the formulation buffer comprises about 1 mM to about 100 mM histidine; wherein the method comprises maintaining the palivizumab, or an antigen-binding fragment thereof, in an aqueous phase at all times during preparation; wherein the liquid formulation of palivizumab, or an antigen-binding fragment thereof, is substantially free of surfactant, inorganic salts and/or other excipients.

3. The method of claim 2, wherein the method does not involve a drying step.

4. The method of claim 2, wherein the formulation buffer comprises histidine at a concentration ranging from about 10 mM to about 50 mM histidine, about 20 mM to about 30 mM histidine, about 23 mM to about 27 mM histidine, or about 25 mM histidine.

5. The method of claim 2, wherein the formulation buffer further comprises glycine at a concentration of less than 150 mM glycine, less than 100 mM glycine, less than 50 mM glycine, less than 3.0 mM glycine, less than 2.0 mM glycine, less than 1.8 mM glycine, or about 1.6 mM glycine.

6. The method of claim 2, wherein the formulation buffer comprises a pH ranging from about 5.0 to about 7.0, about 5.5 to about 6.5, about 5.8 to about 6.2, or about 6.0.

7. The method of claim 2, wherein the formulation buffer comprises 25 mM histidine, 1.6 mM glycine, and pH 6.

8. The method of claim 2, comprising concentrating the preparation of palivizumab, or an antigen-binding fragment thereof, to a concentration of about 15 mg/ml to about 300 mg/ml prior to diafiltration.

9. The method of claim 8, wherein the preparation of palivizumab, or an antigen-binding fragment thereof, is concentrated to a concentration of about 15 mg/ml, about 20 mg/ml, about 30 mg/ml, about 40 mg/ml, about 50 mg/ml, about 60 mg/ml, about 70 mg/ml, about 80 mg/ml, about 90 mg/ml, about 100 mg/ml, about 150 mg/ml, about 200 mg/ml, about 250 mg/ml, or about 300 mg/ml prior to diafiltration.

10. The method of claim 2, wherein the liquid formulation of palivizumab, or an antigen-binding fragment thereof, is diluted to a concentration of 103.+-.3 mg/ml palivizumab, or an antigen-binding fragment thereof.

11. The method of claim 2, further comprising sterilization of the liquid formulation.

12. The method of claim 11, wherein sterilization comprises sterile filtration or radiation.

13. The method of claim 11, wherein sterilization comprises filter sterilization comprising a 0.2 or 0.22 micron filter.

14. The method of claim 2, comprising purifying the preparation of palivizumab, or an antigen-binding fragment thereof, prior to diafiltration.

15. The method of claim 14, wherein purifying the preparation of palivizumab, or an antigen-binding fragment thereof, comprises: HS50 chromatography; benzonase treatment; Protein A chromatography; nanofiltration; low pH treatment; and/or Q chromatography column cycle.

16. The method of claim 2, wherein the preparation of palivizumab, or an antigen-binding fragment thereof, is purified from conditioned cell culture medium.

17. The method of claim 16, wherein purifying palivizumab, or an antigen-binding fragment thereof, from conditioned cell culture medium comprises ion exchange chromatography, affinity chromatography, Protein A chromatography, antigen affinity chromatography, and/or sizing column chromatography.

18. The method of claim 10, wherein the formulation buffer comprises 25 mM histidine, 1.6 mM glycine, and pH 6.

19. The method of 1, wherein the method does not involve a drying step.

20. The method of claim 1, wherein the formulation buffer comprises histidine at a concentration ranging from about 10 mM to about 50 mM histidine, about 20 mM to about 30 mM histidine, about 23 mM to about 27 mM histidine, or about 25 mM histidine.

21. The method of claim 1, wherein the formulation buffer further comprises glycine at a concentration of less than 150 mM glycine, less than 100 mM glycine, less than 50 mM glycine, less than 3.0 mM glycine, less than 2.0 mM glycine, less than 1.8 mM glycine, or about 1.6 mM glycine.

22. The method of claim 1, wherein the formulation buffer comprises a pH ranging from about 5.0 to about 7.0, about 5.5 to about 6.5, about 5.8 to about 6.2, or about 6.0.

23. The method of claim 1, wherein the formulation buffer comprises 25 mM histidine, 1.6 mM glycine, and pH 6.

24. The method of claim 1, wherein the liquid palivizumab formulation or an antigen binding fragment thereof comprises about 15 mg/ml, about 20 mg/ml, about 30 mg/ml, about 40 mg/ml, about 50 mg/ml, about 60 mg/ml, about 70 mg/ml, about 80 mg/ml, about 90 mg/ml, about 100 mg/ml, about 150 mg/ml, about 200 mg/ml, about 250 mg/ml, or about 300 mg/ml of palivizumab.

25. The method of claim 1, wherein the liquid formulation of palivizumab or an antigen-binding fragment thereof, comprises 103.+-.3 mg/ml palivizumab, or an antigen-binding fragment thereof.

26. The method of claim 25, wherein the formulation buffer comprises 25 mM histidine, 1.6 mM glycine, and pH 6.

27. The method of claim 1, further comprising sterilization of the liquid formulation.

28. The method of claim 27, wherein sterilization comprises sterile filtration or radiation.

29. The method of claim 27, wherein sterilization comprises filter sterilization comprising a 0.2 or 0.22 micron filter.

30. The method of claim 1, wherein purifying the preparation of palivizumab, or an antigen-binding fragment thereof, comprises: HS50 chromatography; benzonase treatment; Protein A chromatography; nanofiltration; low pH treatment; and/or Q chromatography column cycle.

31. The method of claim 1, wherein the preparation of palivizumab, or an antigen-binding fragment thereof, is purified from conditioned cell culture medium.

32. The method of claim 31, wherein purifying palivizumab, or an antigen-binding fragment thereof, from conditioned cell culture medium comprises ion exchange chromatography, affinity chromatography, Protein A chromatography, antigen affinity chromatography, and/or sizing column chromatography.

Details for Patent 9,879,067

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Medimmune SYNAGIS palivizumab VIAL 103770 001 1998-06-19   Start Trial MedImmune, LLC (Gaithersburg, MD) 2022-06-14 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19   Start Trial MedImmune, LLC (Gaithersburg, MD) 2022-06-14 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,879,067

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Medtronic
Boehringer Ingelheim
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.